司帕沙星脉冲式给药对COPD急性加重期患者的预防作用

The prevention effect of pulse delivery of Sparfloxacin in patients with COPD during acute exacerbation

目的探讨司帕沙星脉冲式给药对慢性阻塞性肺疾病(COPD)急性加重的预防作用。方法 458例COPD患者随机分为观察组(247例)和对照组(211例),观察组在常规治疗的基础上加司帕沙星,每天0.3克,连续用7天,每2月一次;对照组只给予常规治疗。两组患者于治疗后观察其首次急性发作时间、急性加重的频率、患者症状及血清炎性标志物的水平等情况。结果两组患者治疗后首次急性发作时间、急性加重的频率、患者症状及血清炎性标志物的水平均有显著性差异(P<0.05)。结论司帕沙星脉冲式给药能降低慢性阻塞性肺病患者急性加重的频率,明显改善患者症状。

Objective To investigate the prevention effect of pulse delivery of Sparfloxacin in patients with Chronic obstructive pulmonary disease（COPD） during acute exacerbation. Methods 458 patients with COPD were randomly divided into two groups： observation group （247 cases） and control group（211 cases）. The control group was only treated with conventional therapy, while the observation group was continuously treated with sparfloxacin for 7 days （0.3g per day） with an interval of 2 months, in addition to the conventional therapy. The occurrence of the first acute onset time, acute exacerbation frequency, symptoms and the levels of serum inflammatory markers were observed after treatment. Result The first acute onset time, acute exacerbation frequency, symptoms and the levels of serum inflammatory markers of the both groups were significant difference （P〈0. 05）, comparing after treatment with before. Conclusion It is very effective to treat COPD patients with pulse delivery of Sparfloxaein, which could decrease the frequency of acute exacerbation and had significant improvement in symptoms.